Happy to share our new platform with all the professionals.
MediHeroes is a cross-border B2B medical platform that connects suppliers, service providers, distributors, and all the stakeholders in the MedTech Industry. From Search to Match, MediHeroes members can save years in finding quality medical supplies & services and global communities across the countries.
Join now and enjoy a 90-Day free trial!

Below is a picture of a live project for a (very neat and tidy) re-install of medical gases at the NHS QEQM hospital in Margate, Kent (UK). Never has it been a more crucial time to re-think your strategy for you facilities infrastructure, whether its mechanical systems such as Gas Supply or general consultancy on best practice, Aether Medical gases are ideally pitched and equipped to assist your organisation, whether medical or lab based. I'd like to network with organisations UK wide so please get in touch luke@aethermedicalgases.co.uk

* NHS Hospital/practices
* NHS Dental Practices
* Private Hospitals/practices
* Veterinarian Practices
* Scientific Lab and Manufacturing Facilities

Please check out some case studies of Aethers work:

https://www.aethermedicalgases.com/case-studies

Case Studies – Aether Medical Gases

Case Studies – Aether Medical Gases

Dear PHARMeMED network,

I am excited to join this network! My name is Kevin Davies and I am COO at Certos.

Certos enables lab device manufacturers to cut IT development costs and time by up to 90% by offering a ready-to-use software framework for their equipment.

Our software uses cutting technology such as AI enabling devices to be FDA & GxP compliant.

Send us an email at info@certos.ai to receive a FREE presentation showing how we helped other manufacturers to revolutionize their devices.

Looking forward to sharing insights with you!

Hello everybody. I am new here. I am a medical device sales rep interested in connecting with other medical device professionals.

I'm looking for a clinical affairs director within the US with medical devices experience.
Do you know anyone who may be looking?

The Microcurrent Site is the UK distributor of the AlphaStim Aid - a medical device that uses cranial electrotherapy stimulation to treat anxiety, depression, insomnia and pain.

Steve Hutchinson, Managing Director of the Microcurrent Site, contacted the NIHR for free-of-charge help to set up a research project in the National Health Service (NHS) to generate clinical and health economic data demonstrating the safety and performance of the AlphaStim Aid.

In this video Steve Hutchinson reflects on how his study benefited from the support and expertise of the NIHR research infrastructure embedded in the NHS.

Learn how observation improves medical device effectiveness. StarFish Medical ID & Human Factors experts share tips and insights on conducting observations for procedural, formative, and summative testing. This video includes real examples and explains how to turn observations into design actions.

Justine Bone (@justinembone) is the CEO for MedSec, a company which focuses on medical device security research. They work to secure the endpoints in hospitals, which are proving to be incredibly vulnerable targets due to the diverse population of medical devices.

One of the biggest problems for healthcare facilities is to know what they have, and how/why that can make them vulnerable.
Managing the inventory of medical devices - all the way down to medical implants in people - has become a huge factor for assessing security vulnerabilities for hospitals.

Anyone here from Japan? We are currently hiring professionals within Pharmaceutical and Medical Device industry.

Feel free to contact us if you are keen in learning more about the market and discovering other opportunities in Pharmaceutical or Medical Devices space.

Referral is very much welcome! ☺☺☺

Digital device technology continues to move at a fast pace, which means device manufacturers should keep a close watch on emerging trends and be ready to adapt to new ideas and methodologies.
http://bit.ly/MedicalDeviceTrends2018

This will be especially true for software-enabled products in disposables as well as reusable devices. This white paper examines trends that will significantly impact the medical device industry in 2018 and offers tips on how medical device companies can respond to the trends in order to maintain a strong presence in the industry.

Download free here: http://bit.ly/MedicalDeviceTrends2018

By Stephanie Christopher, Medical Device Innovation Consortium (MDIC)

FDA’s traditional compliance requirements establish a uniform quality system framework, but do not ensure device quality across the ecosystem. Furthermore, a compliance audit will tell a manufacturer whether the system they have established is compliant with current regulations but offers no insight into how they might improve the device, the system, or the development process.

Taking predictive and proactive measures to improve quality can have far-reaching effects – from more efficient resource allocation to decreased probability of a recall.

Conversely, manufacturers that fail to implement quality objectives as value drivers could put the future of their companies at risk. A 2017 McKinsey analysis revealed that the direct cost of quality is $26 billion to $36 billion dollars annually, representing 6.8 to 9.4 percent of device industry sales.

Of that total, two-thirds was the direct cost of poor quality — for example, “labor costs to remediate failures, as well as the material and financial costs of internal and external quality failures.” The other one-third was the direct cost of ensuring good quality — for example, “organizational costs involved in preventing or appraising quality issues.”

Read more: https://www.meddeviceonline.com/doc/proactive-quality-systems-fda-has-made-them-a-priority-has-your-organization-0001

Abbott today announced the U.S. Food and Drug Administration (FDA) approved the Masters HP™ 15mm rotatable mechanical heart valve, the world's smallest mechanical heart valve, that will allow doctors to treat babies and toddlers in need of a mitral or aortic valve replacement. Until today, surgeons could only use a range of larger-sized valves to replace a pediatric heart valve that could not be repaired, and larger valves are often not suitable given the smaller size of children's hearts. This dime-sized new valve is the first and only pediatric mechanical heart valve developed for newborns and infants, and offers hope for pediatric patients in urgent need of treatment who have no other approved options.

Read more: https://www.prnewswire.com/news-releases/fda-approves-the-worlds-smallest-mechanical-heart-valve-for-pediatric-patients-with-heart-defects-300609484.html

Haemostat powders are widely used to manage bleeding during surgery – the powder accelerates clotting and can easily be sprayed onto an area of bleeding using an air spray device. However, there can be a risk of embolism if the spray device is placed too close to a vein.

Using our experience in medical device development, we’ve designed a disposable spray device which can’t cause embolism thanks to it’s ingenious and patented airflow design.

Developed by Team Consulting: https://www.team-consulting.com

Applied Medical Technology, Inc. (AMT) is more than just a manufacturing facility; we are committed to the highest level of quality, safety, and patient care. We are interested in the whole person, not just the device they use.

We are dedicated to bringing products to the market that improve the quality of patients’ and caregivers’ lives. We are able to accomplish this by bridging the gap between the medical device industry and the patient population, through various relations and partnerships. AMT works with professional clinicians, caregivers, patients and their family members to better understand the needs of the enteral nutrition community.

For more information about Applied Medical Technology, Inc. please visit https://www.appliedmedical.net

So far, we’ve considered what an aging populace, emerging countries, and rising chronic disease have to do with the IVD industry.
In the U.S., there’s perhaps no bigger example of change in the healthcare industry than the Patient Protection and Affordable Care
Act (PPACA), more commonly referred to as the Affordable Care Act (ACA). President Barack Obama signed the ACA into law on
March 23, 2010, though individual components of the ACA went into effect over the course of several years.16 This comprehensive
act has already begun to change the ways insurance companies and health care providers deliver healthcare. For the purposes of
this manual, we’re going to take an extremely high-level look at the ACA as it relates to the IVD industry. A thorough analysis of
the impacts of federal health reform would easily fill an entire series of scholarly volumes. Becoming an expert on the intricacies
of the ACA itself is no mean feat, either; the “condensed” version of the legislation is more than 900 pages long! To access the full
document, and to find everything else you ever wanted to know about the ACA, you can visit www.healthcare.gov.

Briefly, the ACA seeks to accomplish several main things:
• Requires U.S. citizens and legal residents to have health insurance
• Provides more access to affordable healthcare
• Reduces the costs of providing healthcare
• Improves the quality of healthcare
• Emphasizes wellness and prevention
• Encourages innovation in healthcare
• Promotes public health16

The most basic premise behind the ACA is that if Americans have affordable choices for health insurance and are encouraged
to stay well in the first place, there will be fewer uninsured people and a greater number of healthy ones. Healthcare costs will
stay under control, because it’s much less expensive to help people stay well than it is to wait for them to develop costly acute
or chronic health conditions. Already, the ACA has led to a substantial reduction in the uninsured population. The National
Conference of State Legislatures estimates that before health reform, 32 million Americans were without even the most basic
health insurance.17 By allowing unmarried, young adults to stay on their parents’ health insurance plans up to age 26, the
expansion of Medicaid, and subsidies for lower-income individuals and families to purchase health coverage through state and
federal exchanges, the ACA has reduced the number of non-elderly uninsured by 9 million people since January 2014.18
Other key provisions of the ACA will have a marked effect on reimbursement for medical care and other healthcare-related costs.
Lifetime policy limits are eliminated and out-of-pocket yearly expenses are capped. Insurance companies are not able to refuse
coverage for pre-existing medical conditions, drop individuals without due cause, or arbitrarily raise premiums. For individuals, this
will result in lower premiums and health care expenses; medical-related bankruptcies may become a thing of the past.
From an IVD standpoint, the implications of this are pretty clear: there are now millions of newly insured people who now have
access to healthcare that they didn’t have a few years ago. These new patients are creating demand for healthcare services from
hospitals, primary care physicians, and labs. IVD companies and clinical labs stand to benefit greatly from this increased demand,
provided they have their products fill the patients’ needs and fit within their (or their insurance companies’) financial constraints.
Despite the potential benefits of the ACA, it has been mired in controversy from the beginning. One of the ACA’s core
mandates is to reduce healthcare costs, which are reaching unsustainable levels (we’ll take a closer look at this particular
trend at the end of Section 1). For now, though, consider this: as a direct result of health reform, Medicare reimbursement
payments have gone down.19 The Centers for Medicare & Medicaid Services (CMS) announced that it will completely
overhaul its clinical laboratory fee schedule (CLFS) – that means adjustments to every single one of its 1,200 codes.20 These
changes won’t happen overnight, of course, but the end result will be the same: reimbursement cuts. In certain baseline test
situations, there may even be no reimbursement at all. 

http://www.insightpharmareports.com/Commercializing-Novel-IVDs-Report/

The world medical device technologies market is mostly propelled by prominent international market players. A few of those players which are engaged with the production of in vitro diagnostic devices account for a very large share of the overall market. The small market players are, however, predominantly hailing from various emerging economies thereby looking for entry into the market. Such moves are anticipated to alter the future scenario of the said market in the years to come.

The evolution in the technologies of medical device has resulted in the breakthroughs in the diagnosis of disease and further in treatment of diseases. Technologies pertaining to the medical industry have brought forth efficiency, sustainability, and efficacy in the healthcare systems. It comes with various hi-tech, cutting edge gadgets like systems of constant glucose monitoring, ultrasounds, and many others. These are a few of the prime growth promoting factors of the world market for medical device technologies.

Some of the major market players that adorn the international market for medical device technologies are Baxter International Inc., Koninklijke Philips N.V., Medtronic plc, Abbott Laboratories, GE Healthcare, Boston Scientific Corporation, Stryker Corporation, Johnson & Johnson, Siemens Healthineers, Cardinal Health Inc., Smith & Nephew plc. and F. Hoffmann-La Roche Ltd.

A recent market intelligence study by Transparency Market Research forecasts that the world market for medical device technologies to expand at a steady CAGR of around 4.6% over the forecast period that extends from the year 2017 to 2025. The said market is expected to attain a market value of around US$ 563,886.5 mn by the year 2025 rising from a market valuation of US$ 377,562.4 mn in the year 2016.

Read more: http://bit.ly/2BYPDrR

The influx of networked devices in the clinical environment has opened the door to faster, more effective treatment, equipping clinicians with tools to help them cope with rising patient numbers.

Yet it also exposes the industry to the multitude of threats associated with the digital world. With such a large focus being placed on the clinical functionality of medical equipment, comparatively little has been spent ensuring they are adequately protected.

During the global WannaCry outbreak, ransomware inflected at least 1,220 pieces of NHS diagnostic equipment, with more being disconnected to stop it spreading further.

Rusty Carter, vice president of product management at Arxan Technologies, points out that medical devices and critical systems in particular were not originally designed to operate in networked environments, leaving the healthcare community easy prey for cyber-criminals.

Read More: http://bit.ly/MedicalDevicesCyberSecurity

Hi I'm looking for a position in Suppy Chain Management.

Soon graduated from a Japanese Language School in Tokyo, double skilled in science and commerce with both technical and commercial experiences, now looking for a position of business developer in the healthcare industry in Japan. Anyone interested?

Can someone provide a list of recently approved medical technology devices.